We’re improving your experience!

×

Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.

Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.

Stay tuned for these updates, and thank you for being part of our community!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04702880
Title A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ROU | POL | NLD | ITA | GRC | ESP | CAN | BEL | AUS

Facility Status City State Zip Country Details
Local Institution - 0075 Birmingham Alabama 35233 United States Details
Local Institution - 0022 Hackensack New Jersey 07601 United States Details
Local Institution - 0002 Durham North Carolina 27710 United States Details
Local Institution - 0060 Cincinnati Ohio 45219 United States Details
Local Institution Cincinnati Ohio 45267 United States Details
Local Institution - 0067 Cleveland Ohio 44106-1716 United States Details
Local Institution - 0081 Nashville Tennessee 37203 United States Details
Local Institution Dallas Texas 75390 United States Details
Local Institution - 0003 Westmead New South Wales 2145 Australia Details
Local Institution - 0023 Greenslopes Queensland 4120 Australia Details
Local Institution - 0001 Malvern Victoria 3144 Australia Details
Local Institution - 0004 Murdoch Western Australia 6150 Australia Details
Local Institution - 0051 Charleroi 6000 Belgium Details
Local Institution - 0034 Gent 9000 Belgium Details
Local Institution - 0050 Liège 4000 Belgium Details
Local Institution - 0012 Edmonton Alberta T6G 1Z2 Canada Details
Local Institution - 0064 Brampton Ontario L6R 3J7 Canada Details
Local Institution - 0045 Heraklion Irakleío 715 00 Greece Details
Local Institution - 0036 Athens 11527 Greece Details
Local Institution - 0038 Athens 185 47 Greece Details
Local Institution - 0030 Peschiera del Garda 37019 Italy Details
Local Institution - 0031 Pisa 56124 Italy Details
Local Institution - 0029 Rozzano 20089 Italy Details
Local Institution - 0073 Sendai Miyagi 980-0873 Japan Details
Local Institution - 0070 Osaka-Sayama City Osaka 589-8511 Japan Details
Local Institution - 0069 Takatsuki Osaka 5698686 Japan Details
Local Institution - 0077 Ina-machi Saitama 362-0806 Japan Details
Local Institution - 0039 Amsterdam Noord-Holland 1081 HV Netherlands Details
Local Institution - 0066 Arnhem 6815 AD Netherlands Details
Local Institution - 0040 Groningen 9700RB Netherlands Details
Local Institution - 0049 Gdansk 80-214 Poland Details
Local Institution - 0048 Łódź 93-338 Poland Details
Local Institution - 0043 Bucharest 022328 Romania Details
Local Institution - 0042 Cluj 400015 Romania Details
Local Institution - 0041 Craiova 200542 Romania Details
Local Institution - 0007 Barcelona Barcelona [Barcelona] 08035 Spain Details
Local Institution - 0021 Madrid 28041 Spain Details
Local Institution - 0005 Majadahonda 28222 Spain Details
Local Institution - 0006 Málaga 29010 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field